CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 692-701

  Zhao, L H ^a   Lin, Q L ^a   Wei, J ^a   Huai, Y L ^a   Wang, K J ^a   Yan, H Y ^a  

^a Peking University Civil Aviation School of Clinical Medicine   (China)

Author keywords

CD44; CD44V6; Colorectal cancer; Immunohistochemistry

Indexed keywords

CD44 PROTEIN, HUMAN; CD44V6 ANTIGEN; HERMES ANTIGEN; ISOPROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; BIOSYNTHESIS; CANCER STAGING; COLORECTAL TUMOR; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN ISOFORMS;

EID: 84923115904     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
2. Zhang SC, Jin W, Liu H, Jin MJ, Chen ZX, Ding ZY, Zheng SS, Wang LJ, Yu YX, Chen K. RPSA Gene mutants associated with risk of colorectal cancer among the Chinese population Asian Pac J Cancer Prev 2013; 14: 7127-7131.
3. Zhang SC, Jin W, Liu H, Jin MJ, Chen ZX, Ding ZY, Zheng SS, Wang LJ, Yu YX, Chen K. Annual report on status of cancer in China, 2010. Chin J Cancer Res 2014; 26: 48-58.
4. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumor progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis 2013; 28: 9-18.
5. Shi J, Zhou Z, Di W, Li N. Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 2013; 13: 182-192.
6. Orian-Rousseau V. CD44, a therapeutic target for metastasizing tumours. Eur J Cancer 2010; 46: 1271-1277.
7. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39: 527-579.
8. Bendardaf R, Algars A, Elzagheid A, Korkeila E, Ristamäki R, Lamlum H, Collan Y, Syrjänen K, Pyrhönen S. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol Rep 2006; 16: 741-746.
9. Guo W, Frenette PS. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 2014; 33: 537-538.
10. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
11. Zlobec I, Günthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L, Lugli A. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology 2009; 55: 564-575.
12. Jung T, Gross W, Zöller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 2011; 286: 15862-15874.
13. Manten-Horst E, Danen EH, Smit L, Snoek M, Le Poole IC, Van Muijen GN, Pals ST, Ruiter DJ. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer Pred Oncol 1995; 64: 182-188.
14. Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y, Baba H. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 2013; 29: 1570-1578.
15. Jackson PA, Green MA, Pouli A, Hubbard R, Marks CG, Cook MG. Relation between stage, grade, proliferation, and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. J Clin Pathol 1995; 48: 1098-1101.
16. Herrera-Gayol A, Jothy S. Adhesion Proteins in the Biology of Breast Cancer: Contribution of CD44. Exp Mol Pathol 1999; 66: 149-156.
17. Herrlich P, Zöller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993; 14: 395-399.
18. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 2002; 62: 2281-2286.
19. Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB, Cai MY. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol 2013; 107: 799-806.
20. Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 2012; 28: 1301-1308.
21. Xiao M, Hu S, Zhang L, Huang J, Jiang H, Cai X. Polymorphisms of CD44 gene and nasopha ryngeal carcinoma susceptibility in a Chinese popuHeider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immuno Immunother 2004; 53: 567-579.
22. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immuno Immunother 2004; 53: 567-579.
23. Li XD, Ji M, Wu J, Jiang JT, Wu CP. Clinic significance of CD44 expression variants expression in colorectal cancer. Tumori 2013; 99: 88-92.
24. Amirghofran Z, Jalali SA, Hosseini SV, Vasei M, Sabayan B, Ghaderi A. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. J Gastrointest Canc 2008; 39: 73-78.
25. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-4756.